[ad_1]

PARIS & SAN FRANCISCO–(BUSINESS WIRE)–Regulatory News:

SpineGuard (FR0011464452 – ALSGD) (Paris:ALSGD), an innovative company
that deploys its DSG® real time digital technology for surgical guidance
intended to secure and streamline skeletal implant placement, announced
today the acceptance of the first scientific paper on the usage of its
DSG sensing technology for guidance of robotic surgical platforms at the
Hamlyn Symposium on Medical Robotics June 24-26th 2019 in London, United
Kingdom.

The feasibility study will present the utilization of DSG measurements,
performed directly in contact with bone during drilling, without the
necessity of X-Rays. The purpose is to provide real-time feedback to
surgical robots and prevent breaches through the cortical bone barrier,
potentially harmful when undetected. The publication is the result of
collaboration between SpineGuard and the ISIR (Institut des Systèmes
Intelligents et de Robotique) of Sorbonne University, CNRS (Centre
National de la Recherche Scientifique) and INSERM (Institut National de
la Santé et de la Recherche Médicale). The Hamlyn Symposium is
recognized as one of the top meetings worldwide about medical robotics.

Stéphane Bette, CEO and co-founder of SpineGuard, said: “We
previously announced our collaboration in the field of surgical robotics
with the ISIR of Sorbonne University, and the resulting intellectual
property. This is the first publication of the experimental results. We
are of course delighted by this major advancement in the demonstration
of DSG utility in robotics. On the heels of our agreements, for the
“smart” DSG embedded pedicle screw and DSG for the dental applications,
this is an important step in our search for strategic industry partners
who wish to incorporate the DSG technology in their surgical assistance
platforms. Capitalizing on our organic PediGuard device business,
optimized and profitable, SpineGuard pursues the strategic turn it
engaged in 2015: the deployment of its DSG technology in new clinically
relevant applications in order to create further growth drivers.”

Guillaume Morel, Professor at the Sorbonne University, adds: «This
publication is a first step we were looking forward to. The Hamlyn
Symposium on Medical Robotics is a conference that regroups every
year to present all that is new and significant in the world of surgical
robotic research. The peer-review process is very strict and uses very
strong selection criteria. It first requires demonstrating novelty and
technical relevance, which is obvious here because no robots have ever
shown autonomous navigation capabilities in bone using a sensing tool
that they manipulate. Moreover, a specificity of this conference is to
also include the clinical relevance in its selection criteria, as
assessed by world-class surgeons in terms of innovation. Precisely on
this aspect, our paper received excellent recognition, which is quite
rare for such novel work. All this encourages us to persevere; we have a
very robust work plan in front of us to explore the multiple
possibilities offered by these first results.”

About SpineGuard®

Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane
Bette, SpineGuard is an innovative company deploying its proprietary
real-time digital technology DSG® (Dynamic Surgical Guidance) to secure
and streamline the placement of implants in the skeleton. SpineGuard
designs, develops and markets medical devices that have been used in
over 70,000 surgical procedures worldwide. Fourteen studies published in
peer-reviewed scientific journals have demonstrated the multiple
benefits DSG® offers to patients, surgeons, surgical staff and
hospitals. Building on these solid fundamentals and several strategic
partnerships, SpineGuard has expanded its technology platform in a
disruptive innovation: the « smart » pedicle screw launched late 2017
and is broadening the scope of applications in dental implantology and
surgical robotics. DSG® was co-invented by Maurice Bourlion, Ph.D.,
Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer.

For further information, visit www.spineguard.com

Disclaimer
The SpineGuard securities may not be offered or
sold in the United States as they have not been and will not be
registered under the Securities Act or any United States state
securities laws, and SpineGuard does not intend to make a public offer
of its securities in the United States. This is an announcement and not
a prospectus, and the information contained herein does and shall not
constitute an offer to sell or the solicitation of an offer to buy, nor
shall there be any sale of the securities referred to herein in the
United States in which such offer, solicitation or sale would be
unlawful prior to registration or exemption from registration.

[ad_2]

Source link